NCT03295227
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +13 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Thymus Neoplasms
Explore clinical trials studying Thymus Neoplasms. Study availability and eligibility vary by location and protocol.
72 public trials
17 recruiting studies
Thymus Neoplasms trial results
NCT01950572
- Conditions
- Adenoma, Adnexal Diseases, Biliary Tract Diseases, +38 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
NCT07598955
- Conditions
- B2 Thymoma, Hemic and Lymphatic Diseases, Lymphatic Diseases, +9 more
- Locations
-
- Peking University Shenzhen Hospital Shenzhen, Guangdong, China
NCT06019468
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +7 more
- Locations
-
- Shanghai Pulmonary Hospital Shanghai, Shanghai Municipality, China
NCT06402708
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +7 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
NCT02633553
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +6 more
- Locations
-
- Kailiang Wu Shanghai, Shanghai Municipality, China
Recruiting
HEARTS Trial for Thoracic Cancers
NCT07132918
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +25 more
- Locations
-
- University of Wisconsin - Madison Madison, Wisconsin, United States
Recruiting
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
NCT06248515
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +7 more
- Locations
-
- Stanford Cancer Institute Palo Alto, California, United States
- Lombardi Comprehensive Cancer Center, Georgetown University Washington D.C., District of Columbia, United States
- University of Chicago Medical Center Chicago, Illinois, United States
- John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States
Recruiting
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
NCT06838910
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +7 more
- Locations
-
- The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China
NCT07181720
- Conditions
- Adenocarcinoma, Adnexal Diseases, Anaplastic Thyroid Carcinomas, +43 more
- Locations
-
- The 901 Hospital of Joint Logistics Support Force of People Liberation Army Hefei, Anhui, China